World Health Organization : Year 1999 ; World Health Organization, Team of Diagnostic Imaging and Laboratory Technology, Laboratory, No. 99.1: World Health Organization Use of Anticoagulants in Diagnostic Laboratory Investigations

By World Health Organization

Book Id: WPLBN0000119425
Format Type: PDF eBook
File Size: 0.9 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1999 ; World Health Organization, Team of Diagnostic Imaging and Laboratory Technology, Laboratory, No. 99.1: World Health Organization Use of Anticoagulants in Diagnostic Laboratory Investigations
Author:	World Health Organization
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Organization, W. H. (n.d.). World Health Organization : Year 1999 ; World Health Organization, Team of Diagnostic Imaging and Laboratory Technology, Laboratory, No. 99.1. Retrieved from http://gutenberg.us/

Description
Medical Reference Publication

Excerpt
1. INTRODUCTION It is imperative that the in vivo state of the quantity in the body fluid under investigation be preserved unchanged for biochemical analysis to justify a medically valid conclusion. This is not always possible when measuring extracellular and cellular components of blood. Platelets and coagulation factors are activated when the blood vessels are punctured, and these processes continue when sample containers are used without an anticoagulant. Coagulation-related changes of some quantities can be largely avoided by using anticoagulants added to the sample containers. The types and concentrations of anticoagulants were defined for the preservation of venous blood sarr~plesa nd are now used for standardized collection of plasma around the world (1). This recommendation compiles the findings described in the literature and those provided by the contributors to this document on the use of anticoagulants. The overview was developed during several meetings and after discussions with experts from the diagnostics industry.

Table of Contents
CONTENTS 1. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4. 2 . DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 2.1 Wholeblood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5. 2.2 Serum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 2.3 Plasma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5. 2.4 Anticoagulants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5. 2.4.1 Ethylene Diamine Tetraacetic Acid (EDTA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 2.4.2 Citrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5. 2.4.3 Heparinates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5. 2.4.4 Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6. 3 . PLASMAORSERUM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 3.1 Advantages of using plasma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 3.2 Disadvantages of plasma over serum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8 3.3 Analytical samples in the serological diagnosis of infectious diseases . . . . . . . . . . . . . . . . . . . . 8 4 . RECOMMENDATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 4.1 Sample collection and transport time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 4.2 Centrifugation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9. 4.2.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4.2.2 Serum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4.2.3 Plasma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 4.3 Storage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 0 4.4 Evaluation of new analytical procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 5 . Table: THE USE OF VARIOUS ANALYTICAL SAMPLES . . . . . . . . . . . . . . . . . . . . . . 11 6 . REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 6